Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial.
Melek Güler-YükselMartijn KuijperReinhard BosEsmeralda MolenaarJasper EmmeringSylvia EshuisAdams HumanFloor ReimannMaarten BoersMarc-Redwart KokPublished in: RMD open (2023)
Patients with active RA aged 65+ treated with prednisolone 5 mg/day for 2 years gained about 1 kg in weight, compared with minimal-non-significant-weight loss on placebo. Our data suggest that the small increase in weight is mostly lean mass, rather than increase or redistribution of fat mass traditionally associated with glucocorticoid treatment.
Keyphrases
- placebo controlled
- body weight
- double blind
- body composition
- weight loss
- phase iii
- rheumatoid arthritis
- phase ii
- clinical trial
- study protocol
- low dose
- bone mineral density
- bariatric surgery
- resistance training
- open label
- phase ii study
- disease activity
- roux en y gastric bypass
- gastric bypass
- body mass index
- weight gain
- ankylosing spondylitis
- high dose
- interstitial lung disease
- randomized controlled trial
- adipose tissue
- newly diagnosed
- electronic health record
- big data
- radiation therapy
- metabolic syndrome
- artificial intelligence
- high intensity
- data analysis
- combination therapy
- skeletal muscle